Myocardial gene therapy using adeno-associated vectors has demonstrated safety but lacks clinical efficacy in heart failure patients so far.
No takes yet. Share an insight, caveat, or question.
Does not support clinical adoption in heart failure; leaves open vector and target optimization for future trials.
Ishikawa et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: